February 2021 marked a shift in the COVID-19 pandemic as more individuals received vaccinations across the nation. Emergency medicine physicians and public health researchers came together to form Grapefruit Testing with partnerships including tens of thousands of community partners from California to Maine.
Christopher Gaeta, President of Grapefruit Testing, began researching drugs for possible COVID-19 treatment at the Perelman School of Medicine at the University of Pennsylvania in March of 2020. Gaeta studies neuroscience and is an active researcher with several dozen publications to his name. He completed a fellowship from Stanford University and is the Editor-in-Chief for the Journal of Collegiate EMS. Gaeta’s inspiration for forming Grapefruit began after hearing how schools, companies, and summer camps were having trouble finding affordable testing.
“I brought together resources that allow us to offer the best testing at a price that is oftentimes at no cost.” Gaeta went onto share that he has leveraged CARES Act support or other novel funding sources to offer large entities COVID-19 testing. The medical director and advisory board consist of former FDA collaborators, leading epidemiologists, and front-line public response leaders to offer turnkey testing services.
The organization offers everything from planning for implementation of testing procedures, oversight of testing, and response plan consulting for positive test results.
As the organization continues to grow, Grapefruit is continuing to offer novel testing and oversight via telehealth medical services. “We work with everyone from local restaurant chains to nationwide car dealerships. My goal is to have testing that I feel comfortable being a patient with. We are fortunate to have the best testing options for rapid and PCR tests, 24-hour turnaround for PCR tests, and a medical team that has cumulatively overseen testing operations for close to 1,000,000 tests since May 2020.